click below
click below
Normal Size Small Size show me how
Immuno 4-30
| Question | Answer |
|---|---|
| upper limb, lateral breast drainage | axillary |
| stomach drainage | celiac |
| duodenum, jejunum drainage | superior mesenteric |
| sigmoid colon drainage | inferior mesenteric |
| rectum (lower portion above the pectinate) | internal iliac |
| anal canal below pectinate line | superfician inguinal |
| testes | para aortic |
| scrotum | superficial inguinal |
| thigh (superficial) | superficial inguinal |
| lateral side of dorsum of foot | popliteal |
| NK activity enhanced by what? | IL12, IFN beta, interferon alpha |
| when will NK kill | lack of MHC I on target cell nonspecific activation signal on target cell |
| opsonize bacteria | IgG |
| neutralize viruses | IgG |
| activate complement | IgG and IgM |
| sensitize mast cells | IgE |
| cytotoxic type 2 hypersensitivity | IgG |
| immune complex type 3 hypersensitivity | IgG |
| hyperacute organ rejection | antibody b cell mediated |
| acute and chronic organ rejection | T cell mediated |
| C1, C2, C3, C4 | viral neutralization |
| C3b, IgG | opsonization |
| C3a, C5a | Anaphylaxis |
| C5a | neutrophil chemotaxis |
| ACE inhibitors are contraindicated with what deficiency? | C1 esterase inhibitor deficiency |
| hereditary angioedema | C1 esterase inhibitor deficiency |
| C3 deficiency | severe, recurrent pyogenic sinus and respiratory tract infections increased susceptibility to type III hypersensitivity reaction |
| increased susceptibility to type 3 hypersenstivitiy reaction | C3 deficiency |
| recurrent Neisseria bactermia | C3-C8 deficiencies |
| DAF (GPI anchored enzyme) deficiency | complement mediated lysis of RBC PNH |
| Inhibits viral protein synthesis by degrading viral mRNA (but not host mRNA) | ribonuclease of interferons |
| increased MHC I and II expression and antigen expresentation in all cells | gamma interferon |
| activates NK cells to kill virus intected cells | interferons |
| inhibit viral protein synthesis | alpha and beta interferons |
| CD markers for macrophages | CD14 CD40 |
| NK cell CD markers | CD16 (binds Fc of IgG) CD56 |
| T cell CD markers | CD3 CD28 |
| B cell CD markers | CD19, CD20, CD21 (receptor for EBV) CD40 |
| bacteria antigen variation of salmonella | 2 flagellar variants |
| borrelia antigen variation | relapsing fever |
| neisseria gonorrhoaea variation | pilus protein |
| virus variation | influenza |
| parasite antigen variation | trypanosomes (programmed rearrangement) |
| live attenuated vaccine induces what kind of response? | cellular |
| inactivated or killed vaccine -> what kind of response? | humoral |
| live attenuated vaccines | Come see small yellow chickens get vaccinated with MMR and polio. small pox, chicken pox, yellow fever mumps, measles, rubella, polio (Sabin) |
| inactivated/killed vaccines | cholera, influenza, hepatitis A, polio (salk), rabies |
| hypersenstivity pneumonitis (farmer's lung) | type 3 hypersensitivity |
| granulomatosis with polangiitis autoAB | c-ANCA |
| anti smooth muscle | autoimmune hepatitis |
| anti glutamate decarboxylase | type I DM |
| anti U1 RNP | mixed connected tissue disorder |
| Anti Jo1 | polymyositis, dermatomyositis |
| no T cell infections | sepsis CMV, EBV, VZV, chornic infection with respiratory/gi viruses candida, PCP |
| no b cell bacterial infections | encapsulated (strep, staph, h. influ, MORAXELLA) |
| no B cell viral infections | enteroviral encephalitis poliovirus (live vaccine contraindicated) |
| no B cell parasite infection | GI giardiasis (no IgA) |
| produce recurrent bacterial infections | no b cell |
| produce more fungal and viral infectiosn | no T cell deficiencies |
| no complement | neisseria (no Myocbacterium avium complex) |
| can be acquired in 20s - 30s, risk of AI disease, lymphoma, sinopulmonary infections | CVID |
| hyper IgE | coarse Faces cold staph Abscesses retained primary Teeth increased IgE dermatologic eczema |
| disemminated mycobacterial infections and salmonella infection | IL12 receptor deficiency decreased Th1 response |
| partial albinism, peripheral neuropathy, recurrent pyogenic infections by staph and strep | chediak higashi syndrome |
| defect in lysosomal regulator trafficking gene | chediak higashi syndrome |
| alpha interferon | Hep B and Hep C kaposi's sarcoma leukemia malignant melaoma |
| oprelvekin (il-11) | thrombocytopeia |
| sargramostim (GM CSF) | recovery of bone marrow |
| filgrastim (G-CSF) | recovery of bone marrow |
| aldesleukin | IL-2 |
| aldesleukin use | renal cell carcinoma metastatic melanoma |
| omalizumab | IgE additional line of treatment for severe asthma |
| rituximab | B cell non Hodgkin's lymphoma |
| trastuzumab | HER2 overexpressing breast cancer |
| adalimumab | TNF alpha |
| adalimumab | Crohn's disease, rheumatoid arthritis psoriatic arthritis |
| infliximab | TNF-alpha Crohn's disease rheumatoid arthritis, psrioatic arthritis, ankylosing spodylitis |
| digoxin immune Fab | antidoe for digoxin intoxication |
| daclizumab | IL-2 prevent acute rejection of renal transplant |